Table 7.

Effect of Saroglitazar on total cholesterol, LDL-C, HDL-C, and triglycerides in hApoB100/hCETP double transgenic mice.

Group	Total cholesterol (mg/dL)	LDL-C (mg/dL)	HDL-C (mg/dL)	Triglycerides (mg/dL)
Control	151.2 ± 7.7	108.1 ± 10.7	43.6 ± 2.5	108.2 ± 14.7
Saroglitazar (0.1 mg/kg)	109.7 ± 6.2*	74.1 ± 5.3*	34.3 ± 3.5	86.8 ± 14.8
Saroglitazar (0.3 mg/kg)	83.9 ± 5.3*	42.7 ± 2.9*	38.4 ± 4.2	68.7 ± 13.4
Saroglitazar (1 mg/kg)	73.1 ± 2.8*	35.3 ± 1.9*	34.0 ± 2.7	52.3 ± 5.7*
Saroglitazar (3 mg/kg)	66.5 ± 5.1*	31.6 ± 3.3*	30.7 ± 2.8*	42.6 ± 5.8*
Saroglitazar (10 mg/kg)	67.0 ± 5.2*	29.9 ± 3.7*	32.8 ± 3.7	41.6 ± 4.1*

All values are measured at the end of treatment (14th day) and values expressed as mean ± SEM. (n = 6).

ED₅₀Value: LDL reduction – 0.11 mg/kg.

^*P < 0.05 as compared to control (ANOVA).